中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1257 records (took 0.043 seconds)

    Mixing circuit
    534.
    发明授权
    Mixing circuit 有权

    公开(公告)号：US11171608B2

    公开(公告)日：2021-11-09

    申请号：US17273868

    申请日：2019-12-06

    Applicant: ACADEMIA SINICA

    Inventor： Yi-Ching Wu ,  Yuh-Jing Hwang ,  Chau-Ching Chiong ,  Bo-Ze Lu ,  Huei Wang

    IPC: H03D7/12 ,  H03D7/14

    Abstract: The present invention is to provide a mixing circuit, comprising: a first transistor; a second transistor; a third transistor; a first connection point connected to a gate terminal of the first transistor, a drain terminal of the second transistor and a source terminal of the third transistor; a second connection point connected to a source terminal of the first transistor and a gate terminal of the second transistor; and a third connection point connected to a drain terminal of the first transistor and a drain terminal of the third transistor.

    DIGITAL POLYMERASE CHAIN REACTION METHOD FOR DETECTING NUCLEIC ACIDS IN SAMPLES
    535.
    发明申请
    DIGITAL POLYMERASE CHAIN REACTION METHOD FOR DETECTING NUCLEIC ACIDS IN SAMPLES 有权

    公开(公告)号：US20210340611A1

    公开(公告)日：2021-11-04

    申请号：US17283809

    申请日：2019-10-09

    Applicant: ACADEMIA SINICA

    Inventor： Kuo-Ping CHIU

    IPC: C12Q1/6855

    Abstract: The present invention relates to a method for detecting nucleic acid (NA) molecules in samples. More particularly, the present invention relates to an improved digital PCR-based method for detecting specific nucleic acid sequence(s). The present invention is useful for research and diagnostic applications with increased sensitivity and accuracy. The present invention also provides a kit for performing the method for assessingnucleic acids in samples as described herein.

    Epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
    537.
    发明授权
    Epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses 有权

    公开(公告)号：US11111276B2

    公开(公告)日：2021-09-07

    申请号：US16597850

    申请日：2019-10-10

    Applicant: Academia Sinica

    Inventor： Han-Chung Wu ,  Chung-Tao Tang

    IPC: C07K14/005 ,  A61K39/39 ,  C12N7/00 ,  A61K39/12 ,  C07K16/10 ,  G01N33/569 ,  A61K39/00

    Abstract: Isolated mutant dengue virus E protein variants are disclosed. The variant comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 and has one or more amino acid residue substitutions at position corresponding to Asn8 (N8), Arg9 (R9), Val12 (V 12) and/or Glu13 (E13). The variant may comprise an amino acid sequence that is at least 90% identical to the SEQ ID NO: 1 and lack an infection-enhancing antibody-binding motif comprising the amino acid sequence of SEQ ID NO: 28 at domain I. An isolated nucleic acid sequence encoding the variant, a plasmid expressing the variant, a plasmid expressing a virus-like particle comprising the variant, a DNA vaccine, and a method of detecting the presence of a dengue virus in a biological sample are also disclosed.

    Inhibition of SCUBE2, a novel VEGFR2 co-receptor, suppresses tumor angiogenesis
    539.
    发明授权
    Inhibition of SCUBE2, a novel VEGFR2 co-receptor, suppresses tumor angiogenesis 有权

    公开(公告)号：US11066466B2

    公开(公告)日：2021-07-20

    申请号：US16091164

    申请日：2017-04-10

    Applicant: Academia Sinica

    Inventor： Ruey-Bing Yang ,  Yuh-Charn Lin

    IPC: C07K16/22 ,  A61K39/395 ,  C07K16/18 ,  A61P35/00 ,  A61K39/00

    Abstract: An isolated anti-SCL)BE2 (Signal peptide-complement protein Clr/CIs, Uegf: and Bmp 1 (CUB)-epidermal growth factor (EGF) domain-containing protein 2) antibody or a binding fragment thereof is disclosed. The anti-SCUBE2 antibody comprises an antigen binding region that specifically hinds to a target domain located within SCUBE2 (SEQ ID NO: 66) and exhibits a property of inhibiting vascular endothelial growth factor (VEGF)-induced angiogenesis. The target domain is selected from the group consisting of the EGF-like motifs 4 to 6 ranging from a.a. position 175 to 323, or the spacer region ranging from a.a. position 441 to 659, or the first cys-rich motif ranging from a.a. position 668 to 725 of SCUBE2 (SEQ ID NO: 66). The anti-SCUBE2 antibody or binding fragment thereof is for use in treating a disease associated with VEGF-induced angiogenesis, or in treating a tumor or inhibiting tumor angiogenesis and cancer cell growth in a subject in need thereof.

    Substituted pyrrolo[2,1-a]phthalazines and benzo[g]pyrrolo[2,1-a]phthalazines for the treatment of cancer
    540.
    发明授权
    Substituted pyrrolo[2,1-a]phthalazines and benzo[g]pyrrolo[2,1-a]phthalazines for the treatment of cancer 有权

    公开(公告)号：US11066412B2

    公开(公告)日：2021-07-20

    申请号：US16764873

    申请日：2018-11-16

    Applicant: Academia Sinica

    Inventor： Te-Chang Lee ,  Tsann-Long Su ,  Tai-Lin Chen

    IPC: C07D487/14 ,  C07D487/22 ,  C07D487/04 ,  A61P35/02 ,  A61K45/06

    Abstract: Disclosed herein are novel bifunctional compounds and their uses for the treatment and/or prophylaxis of cancers. The bifunctional compound disclosed herein has the structure of formula (I), wherein, optionally substituted with one or more substituents independently selected from the group consisting of halo, alkyl, haloalkyl, alkenyl, C(O)H, OH, O(alkyl), O(CO)alkyl, O(aryl), aryl, and —O(CH2)xN(Rb)2; R1 is an alkyl optionally substituted with one or more substituents independently selected from the group consisting of halo, —OR, —O(CO)CH3, —OSO2R, and —OCONHR; R is hydrogen, alkyl, cycloalkyl, or aryl; R2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl, in which the aryl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of C1-6 alkyl, O(alkyl), halo, cyano, nitro, —N(Rc)2, OCH2O—, O(CH2)2O—, pyrrolidinyl, piperidinyl, piperazinyl, morpholino, and 4—(piperido)piperidinyl; R3 is -NRARB, or -NHPhRC, or -NRARB are taken together to form pyrrolidin-l-yl, piperidin-l-yl, piperazin-l-yl, morpholin-4-yl, 4-(piperidin-l-y)piperidin-l-yl, or 4-(piperidin-4-yl)piperidin-l-yl, wherein the piperazin-l-yl or 4-(piperidin-4-yl) piperidin-l-yl is optionally substituted with one or more substituents independently selected from the group consisting of alky, and —(CH2)nCONH(CH2)mNRARB; RA and RB are independently H or C1-C6 alkyl; RC is hydrogen, halo, alkyl, alkenyl, alknyl, O(alkyl), —NHCORa, —NHC(O)ORa, heterocyclyl or aryl, in which the alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, alkyl, haloalkyl, alkenyl C(O)H, OC(O)alkyl, O(aryl), and aryl, in which the aryl is optionally substituted with one or more substituents independently selected from the group consisting of halo, CN, C1-6 alkyl, N(Rc)2, NO2, O(alkyl), —OCH2O—, —O(CH2)2O—,pyrrolidinyl, pepiridinyl, piperazinyl, morpholino, and 4-(piperido)piperidinyl; Ra is C1-6 alkyl or aryl; Rb is C1-10 alkyl, pyrrolidin-l-yl, piperidin-l-yl, piperazin-l-yl, morpholin-4-yl, 4-(piperidin-l-yl)piperidin-l-yl, or 4-(piperidin-4-yl)piperidin-l-yl; Rc, is hydrogen or C1-10 alkyl; and. x, n and m are independently an integral between 1 to 5.

Patent Agency Ranking